STOCK TITAN

Viatris (VTRS) director adds shares as RSUs vest and new grant issued

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Viatris Inc director Leo Frans Groothuis reported routine equity compensation activity. Restricted stock units and related dividend equivalent units that were previously granted vested and were exercised into common stock on March 6, 2026, with a portion of the resulting shares withheld to cover tax liabilities at $14.16 per share.

On the same date, Groothuis received a new grant of 15,890 restricted stock units, each representing one future share of Viatris common stock that will vest on March 6, 2027. After these vesting, settlement, and tax-withholding transactions, he holds 63,437 shares of Viatris common stock directly.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Groothuis Leo Frans

(Last) (First) (Middle)
1000 MYLAN BOULEVARD

(Street)
CANONSBURG PA 15317

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Viatris Inc [ VTRS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/06/2026 M 23,660 A $0 63,567 D
Common Stock 03/06/2026 F 1,243(1) D $14.16 62,324 D
Common Stock 03/06/2026 M 1,175(2) A $0 63,499 D
Common Stock 03/06/2026 F 62(3) D $14.16 63,437 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units $0 03/06/2026 M 23,660 (4) (4) Common Stock 23,660 $0 0 D
Dividend Equivalent Units $0 03/06/2026 M 1,174.4921 (5) (5) Common Stock 1,174.4921 $0 0 D
Restricted Stock Units $0 03/06/2026 A 15,890 (6) (6) Common Stock 15,890 $0 15,890 D
Explanation of Responses:
1. Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of the restricted stock units (RSUs) granted on March 6, 2025.
2. Fractional shares have been rounded up in connection with the settlement described in footnote 5 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan.
3. Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of the dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on March 6, 2025.
4. Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs vested in full on March 6, 2026.
5. Represents DEUs that accrued with respect to the RSUs previously granted on March 6, 2025 and vested on the same schedule as the underlying RSUs. Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11.
6. Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2027.
/s/ Kevin Macikowski, by power of attorney 03/10/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Viatris (VTRS) director Leo Frans Groothuis report in this Form 4?

He reported routine equity compensation activity. Previously granted RSUs and dividend equivalent units vested into common stock, some shares were withheld for taxes, and he received a new RSU grant vesting in 2027, increasing his direct share holdings.

How many new restricted stock units did Viatris (VTRS) grant to Leo Frans Groothuis?

He was granted 15,890 restricted stock units. Each RSU represents the right to receive one share of Viatris common stock, scheduled to vest on March 6, 2027, subject to the original award terms under the company’s 2020 Stock Incentive Plan.

When did Leo Frans Groothuis’s Viatris RSUs and dividend equivalent units vest?

The RSUs and related dividend equivalent units vested and settled on March 6, 2026. At that time they were converted into shares of Viatris common stock, consistent with the one-for-one share rights described in the award footnotes.

Why were some Viatris (VTRS) shares withheld from Leo Frans Groothuis in this filing?

Shares were withheld to cover tax liabilities from the vesting and settlement of RSUs and dividend equivalent units. The Form 4 notes these tax-withholding dispositions used a price of $14.16 per share, rather than being discretionary open-market sales.

How many Viatris (VTRS) shares does Leo Frans Groothuis hold after these transactions?

Following the vesting, conversion, and tax-withholding entries reported, Leo Frans Groothuis directly holds 63,437 shares of Viatris common stock. This total reflects the net result after all related equity compensation settlements on March 6, 2026.

Do the Viatris (VTRS) Form 4 transactions involve open-market buying or selling by Leo Frans Groothuis?

The transactions reflect equity awards and tax withholding, not open-market trades. RSUs and dividend equivalent units converted into shares, and a portion of those shares was delivered back to Viatris to satisfy tax obligations tied to the vesting events.
Viatris Inc Ord Shs

NASDAQ:VTRS

View VTRS Stock Overview

VTRS Rankings

VTRS Latest News

VTRS Latest SEC Filings

VTRS Stock Data

16.21B
1.15B
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
CANONSBURG